Novartis AG (NVS)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 25, 2025 | $3.99 | 2025-03-12 | 2025-03-12 |
| April 19, 2024 | $3.74 | 2024-03-07 | 2024-03-08 |
| March 20, 2023 | $3.50 | 2023-03-09 | 2023-03-10 |
| March 17, 2022 | $3.33 | 2022-03-08 | 2022-03-09 |
| March 15, 2021 | $3.20 | 2021-03-04 | 2021-03-05 |
Dividends Summary
- Novartis AG has issued 22 dividend payments over the past 21 years
- The most recent dividend was paid 193 days ago, on April 25, 2025
- The highest dividend payed out to investors during this period was $3.99 per share
- The average dividend paid during this period was $2.44 per share.
Company News
Novartis showcased new research data across its Cardiovascular, Renal, and Metabolic disease portfolio, presenting 33 abstracts at ASN Kidney Week and AHA Scientific Sessions, highlighting clinical trial results for treatments in kidney and heart conditions.
Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.
Dyne Therapeutics stock surged over 41% after Novartis announced a $12 billion acquisition of Avidity Biosciences, a peer biotech company developing similar muscle disorder therapies using antibody-based treatments.
Novartis is pioneering radioligand therapy, a targeted cancer treatment that shows promising clinical results. The company estimates the market could reach $25-30 billion, but the technology is still nascent and will take 10-15 years to become mainstream.
Incyte Corporation is expected to report strong Q2 2024 earnings, driven by increased sales of its lead drug Jakafi and other newly approved drugs. The company's earnings are likely to benefit from higher royalties from Novartis for the commercialization of Jakafi in ex-U.S. markets.